Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

First Vaccine For Chlamydia Developed By McMaster Researchers

XTALKS VITALS NEWS

Vaccine

The widely protective vaccine is the first of its kind to treat the often-asymptomatic infection.

Tweetables from this article:

Tweet: 113 million people worldwide are affected by chlamydia each year http://ctt.ec/2e14h+113 million people worldwide are affected by chlamydia each year.

Tweet: Chlamydial antigen called BD584, could have protective effects against the most common species of the bacterium http://ctt.ec/2J3BO+Chlamydial antigen called BD584, could have protective effects against the most common species of the bacterium.

Share this!

July 22, 2016 | by Sarah Massey, M.Sc.

A vaccine designed to prevent the common sexually-transmitted infection (STI), chlamydia, has been developed by researchers at the Michael G. DeGroote Institute for Infectious Disease Research at McMaster University. The widely protective vaccine is the first of its kind to treat the often-asymptomatic infection.

It’s estimated that 113 million people worldwide are affected by chlamydia each year, and are at risk of losing fertility as a result of the infection. The results of the McMaster study – published in the journal, Vaccine – found that a chlamydial antigen called BD584, could have protective effects against the most common species of the parasitic bacterium, known as Chlamydia trachomatis.

Chlamydia often goes untreated due to its asymptomatic tendencies, potentially leading to pelvic inflammatory disease, upper genital tract infections and infertility. According to Dr. David Bulir, a former PhD study in medical sciences at McMaster, and lead author on the study, a vaccine for chlamydia could be extremely beneficial for global health.

“Vaccine development efforts in the past three decades have been unproductive and there is no vaccine approved for use in humans,” said Bulir. “Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections.”



Bulir and his colleagues found that BD584 was able to limit chlamydial shedding – a symptom of C. trachomatis infection – by 95 percent. The potential vaccine candidate also decreased the symptoms associated with blocked fallopian tubes, known as hydrosalpinx, by 87.5 percent.

“Not only is the vaccine effective, it also has the potential to be widely protective against all C. trachomatis strains, including those that cause trachoma,” said Steven Liang, a PhD student at McMaster and co-author on the study. Trachoma is an eye infection caused by the chlamydia bacteria and is the number one cause of preventable blindness around the world.

“The vaccine would be administered through the nose,” said Liang, in explaining how the immunization would be delivered. “This is easy and painless and does not require highly trained health professionals to administer, and that makes it an inexpensive solution for developing nations.”

Trachoma affects millions of people in mainly poorer regions around the world. The researchers say they plan to further develop different formulations of the vaccine, and test its effectiveness against other strains of chlamydia.


Keywords: Vaccine, Antigen, Infection


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.